Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + temozolomide vs bevacizumab + temozolomide in first recurrent high-grade glioma
ChiCTR2600127167Phase 4Not yet recruiting
- Sponsor
- Southwest Hospital of Army Medical University
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in glioma, glioblastoma (GBM) and anaplastic glioma comparing Anlotinib + temozolomide with Bevacizumab + temozolomide (2 arms). Primary endpoint: Progression-free survival. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
anlotinibtemozolomidebevacizumab
03
Conditions
gliomaglioblastoma (GBM)anaplastic glioma
Beyond the preview
Go deeper on ChiCTR2600127167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127167.